1	Basic	Basic	B-NP	JJ	B-protein	4	NMOD	-1
2	fibroblast	fibroblast	I-NP	NN	I-protein	4	NMOD	-1
3	growth	growth	I-NP	NN	I-protein	4	NMOD	0
4	factor	factor	I-NP	NN	I-protein	8	NMOD	-1
5	:	:	O	:	O	4	P	-1
6	a	a	B-NP	DT	O	8	NMOD	-1
7	missing	missing	I-NP	JJ	O	8	NMOD	-1
8	link	link	I-NP	NN	O	0	ROOT	-1
9	between	between	B-PP	IN	O	8	NMOD	-1
10	collagen	collagen	B-NP	NN	B-protein	19	NMOD	-1
11	VII	VII	I-NP	CD	I-protein	10	NMOD	-1
12	,	,	O	,	O	19	P	-1
13	increased	increase	B-NP	VBN	O	14	NMOD	17	increased
14	collagenase	collagenase	I-NP	NN	B-protein	19	NMOD	-1
15	,	,	O	,	O	19	P	-1
16	and	and	O	CC	O	19	NMOD	-1
17	squamous	squamous	B-NP	JJ	O	19	NMOD	-1
18	cell	cell	I-NP	NN	O	19	NMOD	-1
19	carcinoma	carcinoma	I-NP	NN	O	9	PMOD	-1
20	in	in	B-PP	IN	O	19	NMOD	-1
21	recessive	recessive	B-NP	JJ	O	24	NMOD	-1
22	dystrophic	dystrophic	I-NP	JJ	O	24	NMOD	-1
23	epidermolysis	epidermolysis	I-NP	NN	O	24	NMOD	-1
24	bullosa	bullosa	I-NP	NN	O	20	PMOD	-1
25	.	.	O	.	O	8	P	-1

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Patients	Patient	B-NP	NNS	O	12	SUB	-1
4	with	with	B-PP	IN	O	3	NMOD	-1
5	recessive	recessive	B-NP	JJ	O	8	NMOD	-1
6	dystrophic	dystrophic	I-NP	JJ	O	8	NMOD	-1
7	epidermolysis	epidermolysis	I-NP	NN	O	8	NMOD	-1
8	bullosa	bullosa	I-NP	NN	O	4	PMOD	-1
9	(	(	O	(	O	11	DEP	-1
10	RDEB	RDEB	B-NP	NN	B-protein	11	DEP	-1
11	)	)	O	)	O	8	NMOD	-1
12	have	have	B-VP	VBP	O	30	VMOD	-1
13	deficiencies	deficiency	B-NP	NNS	O	12	OBJ	9	deficiencies
14	of	of	B-PP	IN	O	13	NMOD	-1
15	collagen	collagen	B-NP	NN	B-protein	16	NMOD	-1
16	type	type	I-NP	NN	I-protein	14	PMOD	-1
17	VII	VII	I-NP	CD	I-protein	16	NMOD	-1
18	and	and	O	CC	O	12	VMOD	-1
19	have	have	B-VP	VBP	O	12	VMOD	-1
20	elevated	elevate	I-VP	VBN	O	19	VC	17	elevated
21	levels	level	B-NP	NNS	O	20	OBJ	-1
22	of	of	B-PP	IN	O	21	NMOD	-1
23	fibroblast	fibroblast	B-NP	NN	B-protein	24	NMOD	-1
24	collagenase	collagenase	I-NP	NN	I-protein	22	PMOD	-1
25	,	,	O	,	O	30	P	-1
26	and	and	O	CC	O	30	NMOD	-1
27	a	a	B-NP	DT	O	30	NMOD	-1
28	greatly	greatly	I-NP	RB	O	29	AMOD	-1
29	increased	increase	I-NP	VBN	O	30	NMOD	0
30	risk	risk	I-NP	NN	O	1	OBJ	-1
31	of	of	B-PP	IN	O	30	NMOD	-1
32	cutaneous	cutaneous	B-NP	JJ	O	35	NMOD	-1
33	squamous	squamous	I-NP	JJ	O	35	NMOD	-1
34	cell	cell	I-NP	NN	O	35	NMOD	-1
35	carcinoma	carcinoma	I-NP	NN	O	31	PMOD	-1
36	.	.	O	.	O	1	P	-1

1	Patients	Patient	B-NP	NNS	O	7	SUB	-1
2	with	with	B-PP	IN	O	1	NMOD	-1
3	other	other	B-NP	JJ	O	6	NMOD	-1
4	genetic	genetic	I-NP	JJ	O	6	NMOD	-1
5	blistering	blistering	I-NP	NN	O	6	NMOD	-1
6	disorders	disorder	I-NP	NNS	O	2	PMOD	-1
7	do	do	B-VP	VBP	O	0	ROOT	-1
8	not	not	I-VP	RB	O	7	VMOD	-1
9	have	have	I-VP	VB	O	7	VC	-1
10	elevated	elevate	I-VP	VBN	O	9	VC	17	elevated
11	collagenase	collagenase	B-NP	NN	B-protein	15	NMOD	-1
12	or	or	O	CC	O	15	NMOD	-1
13	an	an	B-NP	DT	O	15	NMOD	-1
14	increased	increase	I-NP	VBN	O	15	NMOD	0
15	risk	risk	I-NP	NN	O	10	OBJ	-1
16	of	of	B-PP	IN	O	15	NMOD	-1
17	squamous	squamous	B-NP	JJ	O	19	NMOD	-1
18	cell	cell	I-NP	NN	O	19	NMOD	-1
19	carcinoma	carcinoma	I-NP	NN	O	16	PMOD	-1
20	,	,	O	,	O	10	P	-1
21	despite	despite	B-PP	IN	O	10	VMOD	-1
22	chronic	chronic	B-NP	JJ	O	23	NMOD	-1
23	wounding	wounding	I-NP	NN	O	21	PMOD	-1
24	.	.	O	.	O	7	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	connection	connection	I-NP	NN	O	0	ROOT	0
3	between	between	B-PP	IN	O	2	NMOD	-1
4	collagen	collagen	B-NP	NN	B-protein	5	NMOD	-1
5	type	type	I-NP	NN	I-protein	7	NMOD	-1
6	VII	VII	I-NP	CD	I-protein	5	NMOD	-1
7	deficiency	deficiency	I-NP	NN	O	16	SUB	0
8	,	,	O	,	O	16	P	-1
9	increased	increase	B-NP	VBN	O	10	NMOD	17	increased
10	collagenase	collagenase	I-NP	NN	B-protein	16	SUB	-1
11	,	,	O	,	O	16	P	-1
12	and	and	O	CC	O	16	VMOD	-1
13	squamous	squamous	B-NP	JJ	O	15	NMOD	-1
14	cell	cell	I-NP	NN	O	15	NMOD	-1
15	carcinoma	carcinoma	I-NP	NN	O	16	SUB	-1
16	is	be	B-VP	VBZ	O	3	SBAR	-1
17	not	not	I-VP	RB	O	16	VMOD	-1
18	understood	understand	I-VP	VBN	O	16	VC	-1
19	.	.	O	.	O	2	P	-1

1	MATERIALS	MATERIALS	B-NP	NNS	O	3	NMOD	-1
2	AND	AND	I-NP	CC	O	3	NMOD	-1
3	METHODS	METHODS	I-NP	NNS	O	42	NMOD	-1
4	:	:	O	:	O	3	P	-1
5	Urine	Urine	B-NP	NN	O	29	NMOD	-1
6	from	from	B-PP	IN	O	5	NMOD	-1
7	81	81	B-NP	CD	O	8	NMOD	-1
8	patients	patient	I-NP	NNS	O	6	PMOD	-1
9	with	with	B-PP	IN	O	8	NMOD	-1
10	RDEB	RDEB	B-NP	NN	B-protein	9	PMOD	-1
11	(	(	O	(	O	14	DEP	-1
12	39	39	B-NP	CD	O	13	NMOD	-1
13	patients	patient	I-NP	NNS	O	14	DEP	-1
14	)	)	O	)	O	10	NMOD	-1
15	,	,	O	,	O	29	P	-1
16	junctional	junctional	B-NP	JJ	O	18	NMOD	-1
17	epidermolysis	epidermolysis	I-NP	NN	O	18	NMOD	-1
18	bullosa	bullosa	I-NP	NN	O	29	NMOD	-1
19	(	(	O	(	O	24	DEP	-1
20	JEB	JEB	B-NP	NN	B-protein	23	NMOD	-1
21	;	;	O	:	O	23	P	-1
22	12	12	B-NP	CD	O	23	NMOD	-1
23	patients	patient	I-NP	NNS	O	24	DEP	-1
24	)	)	O	)	O	18	NMOD	-1
25	,	,	O	,	O	29	P	-1
26	and	and	O	CC	O	29	NMOD	-1
27	epidermolysis	epidermolysis	B-NP	NN	B-protein	29	NMOD	-1
28	bullosa	bullosa	I-NP	NN	I-protein	29	NMOD	-1
29	simplex	simplex	I-NP	NN	I-protein	42	NMOD	-1
30	(	(	O	(	O	35	DEP	-1
31	EBS	EBS	B-NP	NN	B-DNA	34	NMOD	-1
32	;	;	O	:	O	34	P	-1
33	30	30	B-NP	CD	O	34	NMOD	-1
34	patients	patient	I-NP	NNS	O	35	DEP	-1
35	)	)	O	)	O	29	NMOD	-1
36	,	,	O	,	O	42	P	-1
37	as	as	B-CONJP	RB	O	42	NMOD	-1
38	well	well	I-CONJP	RB	O	37	DEP	-1
39	as	as	I-CONJP	IN	O	37	DEP	-1
40	unaffected	unaffected	B-NP	JJ	O	42	NMOD	0
41	family	family	I-NP	NN	O	42	NMOD	-1
42	members	member	I-NP	NNS	O	51	SUB	-1
43	of	of	B-PP	IN	O	42	NMOD	-1
44	RDEB	RDEB	B-NP	NN	O	45	NMOD	-1
45	patients	patient	I-NP	NNS	O	43	PMOD	-1
46	(	(	O	(	O	49	DEP	-1
47	33	33	B-NP	CD	O	48	NMOD	-1
48	patients	patient	I-NP	NNS	O	49	DEP	-1
49	)	)	O	)	O	42	NMOD	-1
50	,	,	O	,	O	42	P	-1
51	was	be	B-VP	VBD	O	0	ROOT	-1
52	tested	test	I-VP	VBN	O	51	VC	-1
53	for	for	B-PP	IN	O	52	VMOD	-1
54	the	the	B-NP	DT	O	55	NMOD	-1
55	presence	presence	I-NP	NN	O	53	PMOD	14	presence
56	of	of	B-PP	IN	O	55	NMOD	-1
57	basic	basic	B-NP	JJ	B-protein	60	NMOD	-1
58	fibroblast	fibroblast	I-NP	NN	I-protein	60	NMOD	-1
59	growth	growth	I-NP	NN	I-protein	60	NMOD	0
60	factor	factor	I-NP	NN	I-protein	56	PMOD	-1
61	(	(	O	(	O	63	DEP	-1
62	bFGF	bFGF	B-NP	NN	B-protein	63	DEP	-1
63	)	)	O	)	O	60	NMOD	-1
64	using	use	B-VP	VBG	O	51	VMOD	-1
65	a	a	B-NP	DT	O	67	NMOD	-1
66	sensitive	sensitive	I-NP	JJ	O	67	NMOD	0
67	radioimmunoassay	radioimmunoassay	I-NP	NN	O	64	OBJ	-1
68	.	.	O	.	O	51	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	patients	patient	I-NP	NNS	O	3	SUB	-1
3	included	include	B-VP	VBD	O	0	ROOT	-1
4	many	many	B-NP	JJ	O	3	OBJ	-1
5	who	who	B-NP	WP	O	4	NMOD	-1
6	were	be	B-VP	VBD	O	5	SBAR	-1
7	enrolled	enrol	I-VP	VBN	O	6	VC	-1
8	in	in	B-PP	IN	O	7	VMOD	-1
9	the	the	B-NP	DT	O	14	NMOD	-1
10	Epidermolysis	Epidermolysis	I-NP	NNP	O	12	NMOD	-1
11	Bullosa	Bullosa	I-NP	NNP	O	12	NMOD	-1
12	Registry	Registry	I-NP	NNP	O	14	NMOD	-1
13	and	and	O	CC	O	14	NMOD	-1
14	others	other	B-NP	NNS	O	8	PMOD	-1
15	who	who	B-NP	WP	O	14	NMOD	-1
16	were	be	B-VP	VBD	O	15	SBAR	-1
17	referred	refer	I-VP	VBN	O	16	VC	-1
18	by	by	B-PP	IN	O	17	VMOD	-1
19	their	their	B-NP	PRP$	O	20	NMOD	-1
20	physicians	physician	I-NP	NNS	O	18	PMOD	-1
21	.	.	O	.	O	3	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	Fifty-one	Fifty-one	B-NP	CD	O	4	NMOD	-1
4	percent	percent	I-NP	NN	O	9	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	patients	patient	B-NP	NNS	O	5	PMOD	-1
7	with	with	B-PP	IN	O	6	NMOD	-1
8	RDEB	RDEB	B-NP	NN	B-protein	7	PMOD	-1
9	had	have	B-VP	VBD	O	1	NMOD	-1
10	elevated	elevate	I-VP	VBN	O	11	NMOD	17	elevated
11	levels	level	B-NP	NNS	O	9	OBJ	-1
12	(	(	O	(	O	17	DEP	-1
13	greater	great	B-NP	JJR	O	14	AMOD	-1
14	than	than	I-NP	IN	O	16	NMOD	-1
15	5000	5000	I-NP	CD	O	14	AMOD	-1
16	pg/g	pg/g	I-NP	NN	O	17	DEP	-1
17	)	)	O	)	O	11	NMOD	-1
18	of	of	B-PP	IN	O	11	NMOD	-1
19	urinary	urinary	B-NP	JJ	B-protein	20	NMOD	-1
20	bFGF	bFGF	I-NP	NN	I-protein	18	PMOD	-1
21	.	.	O	.	O	1	P	-1

1	In	In	B-PP	IN	O	10	VMOD	-1
2	contrast	contrast	B-NP	NN	O	1	PMOD	-1
3	,	,	O	,	O	10	P	-1
4	none	none	B-NP	NN	O	10	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	the	the	B-NP	DT	O	7	NMOD	-1
7	patients	patient	I-NP	NNS	O	5	PMOD	-1
8	with	with	B-PP	IN	O	7	NMOD	-1
9	JEB	JEB	B-NP	NN	B-protein	8	PMOD	-1
10	had	have	B-VP	VBD	O	0	ROOT	-1
11	elevated	elevate	I-VP	VBN	O	12	NMOD	17	elevated
12	levels	level	B-NP	NNS	O	10	OBJ	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	bFGF	bFGF	B-NP	NN	B-protein	13	PMOD	-1
15	.	.	O	.	O	10	P	-1

1	Twenty-one	Twenty-one	B-NP	CD	O	2	NMOD	-1
2	percent	percent	I-NP	NN	O	8	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	clinically	clinically	B-NP	RB	O	5	AMOD	-1
5	unaffected	unaffected	I-NP	JJ	O	7	NMOD	0
6	family	family	I-NP	NN	O	7	NMOD	-1
7	members	member	I-NP	NNS	O	3	PMOD	-1
8	had	have	B-VP	VBD	O	16	VMOD	-1
9	elevated	elevate	I-VP	VBN	O	10	NMOD	17	elevated
10	levels	level	B-NP	NNS	O	8	OBJ	-1
11	of	of	B-PP	IN	O	10	NMOD	-1
12	bFGF	bFGF	B-NP	NN	B-protein	11	PMOD	-1
13	,	,	O	,	O	16	P	-1
14	and	and	O	CC	O	16	NMOD	-1
15	13	13	B-NP	CD	O	16	NMOD	-1
16	%	%	I-NP	NN	O	21	SUB	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	patients	patient	B-NP	NNS	O	17	PMOD	-1
19	with	with	B-PP	IN	O	18	NMOD	-1
20	EBS	EBS	B-NP	NN	B-DNA	19	PMOD	-1
21	had	have	B-VP	VBD	O	0	ROOT	-1
22	elevated	elevate	I-VP	VBN	O	23	NMOD	17	elevated
23	levels	level	B-NP	NNS	O	21	OBJ	-1
24	of	of	B-PP	IN	O	23	NMOD	-1
25	bFGF	bFGF	B-NP	NN	B-protein	24	PMOD	-1
26	.	.	O	.	O	21	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	frequency	frequency	I-NP	NN	O	10	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	elevated	elevated	B-NP	JJ	O	6	NMOD	17	elevated
5	bFGF	bFGF	I-NP	NN	O	6	NMOD	-1
6	values	value	I-NP	NNS	O	3	PMOD	-1
7	among	among	B-PP	IN	O	6	NMOD	-1
8	all	all	B-NP	DT	O	9	NMOD	-1
9	groups	group	I-NP	NNS	O	7	PMOD	-1
10	was	be	B-VP	VBD	O	27	VMOD	-1
11	statistically	statistically	B-ADJP	RB	O	10	VMOD	-1
12	significant	significant	I-ADJP	JJ	O	10	PRD	-1
13	(	(	O	(	O	17	DEP	-1
14	p	p	B-NP	NN	O	16	SUB	-1
15	=	=	B-VP	SYM	O	16	VMOD	-1
16	0.002	0.002	B-NP	CD	O	17	DEP	-1
17	)	)	O	)	O	10	VMOD	-1
18	,	,	O	,	O	27	P	-1
19	and	and	O	CC	O	21	NMOD	-1
20	the	the	B-NP	DT	O	21	NMOD	-1
21	levels	level	I-NP	NNS	O	27	SUB	-1
22	of	of	B-PP	IN	O	21	NMOD	-1
23	bFGF	bFGF	B-NP	NN	B-protein	22	PMOD	-1
24	in	in	B-PP	IN	O	21	NMOD	-1
25	RDEB	RDEB	B-NP	NN	O	26	NMOD	-1
26	patients	patient	I-NP	NNS	O	24	PMOD	-1
27	were	be	B-VP	VBD	O	0	ROOT	-1
28	significantly	significantly	B-ADJP	RB	O	27	VMOD	-1
29	elevated	elevated	I-ADJP	JJ	O	27	PRD	17	elevated
30	compared	compare	B-PP	VBN	O	29	AMOD	-1
31	with	with	B-PP	IN	O	30	PMOD	-1
32	those	those	B-NP	DT	O	31	PMOD	-1
33	of	of	B-PP	IN	O	32	NMOD	-1
34	other	other	B-NP	JJ	O	35	NMOD	-1
35	groups	group	I-NP	NNS	O	33	PMOD	-1
36	(	(	O	(	O	41	DEP	-1
37	p	p	B-NP	NN	O	41	DEP	-1
38	less	less	B-ADJP	JJR	O	37	NMOD	-1
39	than	than	B-PP	IN	O	38	AMOD	-1
40	0.05	0.05	B-NP	CD	O	39	PMOD	-1
41	)	)	O	)	O	32	NMOD	-1
42	.	.	O	.	O	27	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	We	We	B-NP	PRP	O	4	SUB	-1
4	have	have	B-VP	VBP	O	1	NMOD	-1
5	found	find	I-VP	VBN	O	4	VC	0
6	that	that	B-SBAR	IN	O	5	VMOD	-1
7	patients	patient	B-NP	NNS	O	10	SUB	-1
8	with	with	B-PP	IN	O	7	NMOD	-1
9	RDEB	RDEB	B-NP	NN	B-protein	8	PMOD	-1
10	have	have	B-VP	VBP	O	6	SBAR	-1
11	elevated	elevate	I-VP	VBN	O	10	VC	17	elevated
12	levels	level	B-NP	NNS	O	11	OBJ	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	bFGF	bFGF	B-NP	NN	B-protein	13	PMOD	-1
15	,	,	O	,	O	14	P	-1
16	which	which	B-NP	WDT	O	14	NMOD	-1
17	may	may	B-VP	MD	O	16	SBAR	-1
18	contribute	contribute	I-VP	VB	O	17	VC	0
19	to	to	B-PP	TO	O	18	VMOD	-1
20	increased	increase	B-NP	VBN	O	22	NMOD	17	increased
21	fibroblast	fibroblast	I-NP	NN	O	22	NMOD	-1
22	collagenase	collagenase	I-NP	NN	B-protein	25	NMOD	-1
23	and	and	O	CC	O	25	NMOD	-1
24	the	the	B-NP	DT	O	25	NMOD	-1
25	development	development	I-NP	NN	O	19	PMOD	2	development
26	of	of	B-PP	IN	O	25	NMOD	-1
27	squamous	squamous	B-NP	JJ	O	29	NMOD	-1
28	cell	cell	I-NP	NN	O	29	NMOD	-1
29	carcinoma	carcinoma	I-NP	NN	O	26	PMOD	-1
30	.	.	O	.	O	1	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	results	result	I-NP	NNS	O	3	SUB	0
3	suggest	suggest	B-VP	VBP	O	0	ROOT	-1
4	a	a	B-NP	DT	O	6	NMOD	-1
5	novel	novel	I-NP	JJ	O	6	NMOD	-1
6	treatment	treatment	I-NP	NN	O	3	OBJ	0
7	for	for	B-PP	IN	O	6	NMOD	-1
8	RDEB	RDEB	B-NP	NN	B-protein	7	PMOD	-1
9	,	,	O	,	O	10	P	-1
10	namely	namely	B-ADVP	RB	O	8	NMOD	-1
11	,	,	O	,	O	10	AMOD	-1
12	angiogenesis	angiogenesis	B-NP	NN	O	13	NMOD	3	angiogenesis
13	inhibitors	inhibitor	I-NP	NNS	O	11	ROOT	-1
14	,	,	O	,	O	13	P	-1
15	which	which	B-NP	WDT	O	13	NMOD	-1
16	may	may	B-VP	MD	O	15	SBAR	-1
17	antagonize	antagonize	I-VP	VB	O	16	VC	0
18	the	the	B-NP	DT	O	19	NMOD	-1
19	effects	effect	I-NP	NNS	O	17	OBJ	0
20	of	of	B-PP	IN	O	19	NMOD	-1
21	bFGF	bFGF	B-NP	NN	B-protein	20	PMOD	-1
22	in	in	B-PP	IN	O	19	NMOD	-1
23	this	this	B-NP	DT	O	24	NMOD	-1
24	disorder	disorder	I-NP	NN	O	22	PMOD	-1
25	.	.	O	.	O	13	P	-1

1	There	There	B-NP	EX	O	2	SUB	-1
2	are	be	B-VP	VBP	O	0	ROOT	-1
3	currently	currently	B-ADVP	RB	O	2	VMOD	-1
4	no	no	B-NP	DT	O	6	NMOD	-1
5	other	other	I-NP	JJ	O	6	NMOD	-1
6	means	mean	I-NP	NNS	O	2	PRD	-1
7	of	of	B-PP	IN	O	6	NMOD	-1
8	treatment	treatment	B-NP	NN	O	7	PMOD	0
9	for	for	B-PP	IN	O	8	NMOD	-1
10	this	this	B-NP	DT	O	11	NMOD	-1
11	disorder	disorder	I-NP	NN	O	9	PMOD	-1
12	,	,	O	,	O	11	P	-1
13	which	which	B-NP	WDT	O	11	NMOD	-1
14	has	have	B-VP	VBZ	O	13	SBAR	-1
15	a	a	B-NP	DT	O	20	NMOD	-1
16	high	high	I-NP	JJ	O	17	NMOD	-1
17	morbidity	morbidity	I-NP	NN	O	20	NMOD	-1
18	and	and	I-NP	CC	O	20	NMOD	-1
19	mortality	mortality	I-NP	NN	O	20	NMOD	-1
20	rate	rate	I-NP	NN	O	14	OBJ	-1
